TEQ102

News alerts, weekly reports and conference planners

Company:

Cureteq, Tubulis

Drug class:

Microtubule inhibitor, CD30-targeted antibody-drug conjugate

TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Hodgkin Lymphoma	TNFRSF8 expression	Hodgkin Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D

Associations
(3)